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spread use of the EQ-5D a number of country-specific scoring systems have been
developed. The objective of this study was to identify and compare all existing
EQ-5D valuation studies and country-specific scoring systems.METHODS:An elec-
tronic search of MEDLINE, EMBASE, NHS EED, HEED and a search through the past
proceedings of the Euroqol group up to September of 2010 was conducted to iden-
tify all EQ-5D preference elicitation studies. The review included a summary and
comparison of study design, model estimation, study demographics and scoring
function. RESULTS: After screening 2940 citations identified from the literature
search, 33 elicitation studies that contained a unique scoring systemwere included
for final review. The key areas of divergence between the studies include: differ-
ences in methodology used to directly value health (i.e. SG, TTO, etc.), the number
of health states that were directly valued, the transformation of the directly valued
health states, the statistical methods used to derive the scoring system, and the
model variables included in the scoring system. CONCLUSIONS: Differences in
methods do exist between population studies. Knowing the extent, at which the
identified methodological differences can explain the variation, will help deter-
mine whether a global preference for health exists.
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OBJECTIVES: TheMVH protocol uses a valuation subset of 43 EQ-5D states. Smaller
valuation subsets would allow smaller samples if all respondents can value one set
of states. This study tests the performance of valuation subsets based on orthogo-
nal experiment designs. VAS values obtained for EQ-5D states are affected by the
identity of adjacent states in the elicitation. This study also tests a VAS protocol
developed to minimize such effects. METHODS: 230 respondents were each ran-
domly assigned to one of two orthogonal EQ-5D valuation subsets. EQ-5D states
were printed on 9cm x 4cm cards with rhomboid edges. Respondents first ranked a
shuffled deck of 23 cards. A 1 meter VAS was then placed next to the ranked cards.
Respondents transferred the cards on to the VASwith the rhomboid edges pointing
to the respective values. They could see all of the cards in place at the same time.
Ties were permitted and respondents were free to change the order of states in
moving the cards from the ranked order to the VAS. RESULTS: OLS regression of
VAS Scores produced internally valid models for both valuation subsets with r2 of
0.54 and 0.56. Within sample comparisons of model versus observed VAS values
produced residuals of MAD 3% with individual values crossing 6 VAS points in
only 2 cases. Rank correlation coefficients between model and observed states
0.996. Comparisons across the two subsets/subgroups produced residuals of
MAD4 VAS points and rank correlation coefficients of 0.98 and 0.96.
CONCLUSIONS: This study suggests that orthogonal experiment designs may be
suitable as the basis for the construction of EQ-5D valuation subsets, which can
allow for smaller respondent samples. The statistical properties of the models
arising in this study suggest that some concerns with VAS methods for EQ-5D
elicitations may be reduced using this protocol.
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OBJECTIVES: Patient-reported outcome (PRO), health-related quality of life
(HRQOL), and related instruments are increasingly used in outcomes research. In
developing and evaluating PRO, HRQOL, and related instruments, measurement
validity is a fundamental consideration. With an eye toward investigating the
methodology of validity and uses of validation, we systematically reviewed the
reporting of validation practice in papers published in Value in Health, the Inter-
national Society for Pharmacoeconomics and Outcomes Research (ISPOR) official
journal. METHODS: A systematic search using the journal official website was
conducted inDecember 2010 – including papers since its inception (January 1998) to
December 2010. Two searches were independently conducted by two of the au-
thors. Keywords used in the search included “development OR measurement OR
psychometric OR psychometrics OR valid OR validation OR validity.” We searched
both the titles (126 citations) and abstracts (347 citations). Papers reporting empir-
ical results on validitywere included. Econometric, opinion, and conference papers
were excluded. A coding sheet was developed and each article was double-coded
independently by at least two of the authors. RESULTS: Ninety-three articles met
the inclusion criteria. The percentage of reports of the broad categories of validity
evidencewere: construct (39.8%), discriminant (28.0%), convergent (26.9%), content
(17.2%), concurrent (14.0%), predictive (5.4%), response processes (4.3%), and con-
sequences (1.1%). A paper may report more than one type of validity evidence. In
addition, 95.7% of the papers referred to the validity of the instrument, rather than
the modern view of validity of the inferences from the scores. CONCLUSIONS:
Findings reveal that validity information is not routinely presented from amodern
validity perspective; that is, consider a unitary view of validity, cite recent theoret-
ical papers in validity theory, or distinguish between validity (as a property) and
validation (as a process/method). Some sources of validity evidence (e.g., conse-
quences and response processes) are essentially ignored.
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OBJECTIVES: To establish the concept that it is best practice to provide training to
patients on how to utilize electronic patient reported outcome (ePRO) systems
before patients begins study participation. METHODS: Methods on how to ap-
proach training patients on ePRO systemswill be presented and recommendations
will be discussed. To provide supporting evidence and information on best prac-
tices used in ePRO, a literature review was conducted to identify articles reporting
on studies that utilized ePRO. Of that, articles were identified that reported provid-
ing training to their patients on the ePRO portion of the study prior to participation.
Rates of ePRO compliance are examined and approaches to training patients are
identified within the articles. RESULTS: Out of the 115 articles identified using
ePRO, 55 (47.8%) reported providing ePRO training to their patients. ePRO compli-
ance rates of studies with patient training were overall high (Mean85.08, Stan-
dard Deviation9.83). Training methods reported included: training session, pro-
viding demonstration, giving instruction, question/answer session, subject
hands-on practice, written instructions/reference material, and testing of mastery
of ePRO tool. Duration of training reported ranged from 1 minute to 4 hours.
CONCLUSIONS: Best practice for training patients is to have a combination of the
methods reported above. Having available a dummy system for training is most
important so that demonstration can be provided, patients can practice using the
system and patients can see exactly what they need to do during their actual study
participation. Questions can be addressed and patients can begin the study with a
clearer understanding of what to do during participation. Training patients allows
for higher comfort levels in use of system, thus alleviating frustration and burden.
Furthermore, when patients are trained, they require less support throughout the
duration of the study. Overall, training patients will lead to better experiences for
patient participation.
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OBJECTIVES:Assessments composed of patient-reported outcome (PRO)measures
can be used in health care settings as screeners for various conditions. The objec-
tive of developing and using a PRO screening measure may be to quickly identify
patients who are likely to benefit from a formal diagnostic evaluation. Alterna-
tively, the development objective may be to avoid unnecessary diagnostic proce-
dures, particularly when these are time or resource-intensive or invasive in nature.
The PRO screener may also be administered to simply rule out the existence of a
particular condition. The evaluation of a PRO screening assessment ideally occurs
through analyses using a “gold standard” diagnosis of the condition of interest.
METHODS: A number of existing statistical and psychometric methods may be
used in such an evaluation, including sensitivity and specificity, positive and neg-
ative predictive value, kappa, accuracy, odds ratio, and likelihood ratio. RESULTS:
The evaluation method selected depends on the objective of the screener itself. If
the formal diagnostic procedures are particularly invasive or time- or resource-
intensive, then screeners should minimize false positives; in contrast, diseases
with exceptional riskswhen left undiagnosed call for screeners thatminimize false
negatives. In this research, we explore these methods using data from a study
comparing various fibromyalgia screening instruments with the currently ac-
cepted gold standard diagnosis for fibromyalgia, namely the American College of
Rheumatology 1990 diagnostic criteria (Wolfe et al., 1990). CONCLUSIONS: Using
the example application, we illustrate the pros and cons of a battery of statistical
methods and how they can be used to select the “best” candidate screener.
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OBJECTIVES: In its guidance on the use of PRO measures, the FDA recommends
that sponsors provide evidence that the content validity and other measurement
properties are adequately similar across all versions used in a clinical trial. One
way to ensure the comparability of content is to ensure that all translations reflect
the original item intent. As this presupposes the existence of a formal description
of each item concept, it is the objective of this study to investigate if this was the
case prior to the guidance publication and to make recommendations on the basis
of our findings.METHODS: The research is based on the review of PRO translations
performed between 1995 and 2009. RESULTS: A total of 640 questionnaires (27
generic and 613 disease- or condition-specific) were translated. All were developed
before the publication of the FDA’s PRO guidance. None had a formal written doc-
ument listing a definition of each item concept and possible translation alterna-
tives available before launching the translations. In all cases, the item-by-item
concept list and the list of translation alternatives were developed in collaboration
with the developers of the original questionnaires during the translation process.
In some cases (multiple projects involving different languages for the same ques-
tionnaire), the development of the concept list was a dynamic process fed by ques-
tions raised at each new translation [e.g. Quality of Life in Inflammatory Bowel
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